Illumina (ILMN) has entered a multiyear partnership with Ovation.io to develop a dataset with integrated clinical multiomic insights from 25,000 patients treated with glucagon-like peptide-1 therapies, the companies said Thursday.
The commercially available dataset is expected to help the pharmaceutical industry advance drug discovery and development, the companies said.
Under the agreement, Ovation.io will supply genome samples from its biobank, which will be sequenced by Illumina, they said.
The initial phase of the collaboration prioritized developing datasets from patients with liver and chronic kidney disease, as well as those treated with GLP-1 receptor agonists. The companies intend to scale the GLP-1 dataset moving forward.
Price: 77.84, Change: +0.24, Percent Change: +0.31
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.